Company intelligence / Profile preview

Ventracor

Sydney*, New South Wales*, Australiapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

The VentrAssist LVAD demonstrated strong clinical results, with one-year survival rates up to 74% in end-stage heart failure patients—historically expected at around 50%. In CE Mark Bridge to Transplant trials, survival was about 85%. Some patients improved enough that the device could be explanted after cardiac recovery. Over 100 patients were implanted globally by mid/late 2000s. The product was market released in Europe and Australia but had not completed FDA approval before the company's collapse.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Ventracor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ventracor.

Explore the full profile